Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.

Yan-Ting ChenErik T ValentErik H van BeersRowan KuiperStefania OlivaTorsten HaferlachWee-Joo ChngMartin H van VlietPieter SonneveldAlessandra Larocca

Published in: International journal of laboratory hematology (2021)

For the first time, this study confirmed the prognostic value of GEP markers outside clinical trials. Conventional prognostic models to define high-risk MM are improved by the incorporation of GEP markers.

Keyphrases

clinical trial
gene expression
multiple myeloma
phase ii
dna methylation
open label
randomized controlled trial
phase iii
data analysis
placebo controlled